Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
Protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in Crohn\'s Disease Activity Index (CDAI) of at least 100 points) in Protocol 603. Protocol 610 is evaluating the length of initial effect of PROCHYMAL® adult human mesenchymal stem cells and the ability of these cells to successfully re-induce clinical benefit.
Epistemonikos ID: 537479e2df8ccae81c1a642234cb9546a0f3ae53
First added on: May 04, 2024